Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

Published:2013-03 Issue:3 Volume:8 Page:270-278
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Garon Edward B.,Pietras Richard J.,Finn Richard S.,Kamranpour Naeimeh,Pitts Sharon,Márquez-Garbán Diana C.,Desai Amrita J.,Dering Judy,Hosmer Wylie,von Euw Erika M.,Dubinett Steven M.,Slamon Dennis J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IMMUNOFLUORESCENCE ANALYSIS OF ESTROGEN RECEPTORS ALPHA EXPRESSION IN NON-SMALL CELL LUNG CANCER TISSUE;Lomonosov chemistry journal;2024-06-07

2. Immunofluorescence Analysis of Estrogen Receptors Alpha Expression in Non-Small Cell Lung Cancer Tissue;Moscow University Chemistry Bulletin;2024-06

3. G protein-coupled estrogen receptor activates PI3K/AKT/mTOR signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis;Molecular Medicine;2024-02-21

4. Cisplatin-activated ERβ/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis;Drug Resistance Updates;2023-11

5. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy;The Breast;2023-10